(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
Share This 
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
Share This 
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Share This 
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Share This 
PCR platforms and Good Manufacturing Practices (GMP) certification further enhance European service offerings HAMBURG, GERMANY and DURHAM, NC, May 8,
Share This 
BioAgilytix continues to build leadership in Europe. Hamburg, Germany April 3, 2023 – BioAgilytix, a leading global bioanalytical laboratory, today
Share This This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
Share This 
As we continue our blog series on flow cytometry, we’ll now dive into how this powerful capability supports multiple types
Share This 
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
Share This 
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
Share This This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
Share This In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Share This Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Share This PCR platforms and Good Manufacturing Practices (GMP) certification further enhance European service offerings HAMBURG, GERMANY and DURHAM, NC, May 8,
Share This BioAgilytix continues to build leadership in Europe. Hamburg, Germany April 3, 2023 – BioAgilytix, a leading global bioanalytical laboratory, today
Share This This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
Share This As we continue our blog series on flow cytometry, we’ll now dive into how this powerful capability supports multiple types
Share This Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
Share This
For Peptide, Antibody, Hormone, And Protein Detection
Enzyme-linked immunosorbent assays (ELISA) are the most common method for ligand binding assays, and are a core competency for the BioAgilytix team. We use ELISA in both its original and automation-powered forms as a fast, reliable, and cost-effective platform for analyte quantification of specific assays used for testing of biologics as well as cell and gene therapies.
What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements
with one of our scientists.
The ELISA method is designed for detecting and quantifying substances such as peptides, proteins, antibodies and hormones, and is typically performed on a 96-well plate. Using ELISA, detection is completed by assessing the conjugated enzyme activity via incubation with a substrate to produce a measurable signal.
The binding and immobilization of reagents done through ELISA makes it easy to separate bound from non-bound material during the assay, and wash away non-specifically bound materials to measure specific analytes.
The ELISA technique was originally developed in the 1970s, when it was created as a replacement for traditional radioimmunoassay methods. More recently however, the ELISA method has been paired with laboratory automation techniques to dramatically improve throughput and sensitivity. Such advancements include automated plate washing and automated readouts.
Learn why ELISA is still the most used immunoassay platform for supporting large molecule bioanalysis in this featured blog from a platform expert.
The ELISA method is one of the most diverse available, with applications throughout health care and large molecule laboratory science. The platform comes in a variety of mechanisms, including direct, indirect, sandwich, competitive and ELISpot, each with its own optimal applications.
As a bioanalytical laboratory that harnesses a variety of platforms, BioAgilytix most frequently leverages ELISA in our work with biomarkers, immunogenicity, pharmacokinetics (PK), and cell-based assays. ELISA can be leveraged in a multitude of research areas, including oncology, cardiovascular, neuroscience, and gene and cell therapies. Specifically, ELISA can be used to evaluate antibodies to specific HLA haplotype expressed by allogenous cell therapy, and supports assessment of immunogenicity, both humoral and cellular response, to the transgene, vector, and lipid nanoparticle used in cell and gene therapies.
Even after more than 40 years of widespread use, the ELISA method is still widely regarded for its many advantages. Aside from its original benefit of not requiring radioisotopes or radiation-measurement equipment and its use of fluorescence, ELISAs offer high sensitivity, specificity, adaptability and reliability when compared to other techniques.
The ELISA plate will passively bind antibodies and proteins, and is then developed by adding an enzymatic substrate to produce a visible signal that indicates the quantity of antigen is captured on a plate and followed by incubation with the detection antibody.
This binding and immobilization of reagents makes it easy to separate bound from nonbound material during the assay, and wash away nonspecifically bound materials to measure specific analytes.
Platform In Action
Learn how automation is helping analysts address growing pressures to increase efficiency and output with limited resources.
BioAgilytix offers ELISA services as a central competency, and has extensive experience developing, optimizing, and validating ELISA tests. Our team is proficient in single analyte and multiplexed analyses, with traditional colorimetric readouts as well as electrochemoluminescence readouts with MSD technology. We run bioanalytical ELISA assays across the range of biological matrices — from serum and plasma to urine and cell and tissue lysate. In fact, we have developed ELISA assays for:
Our equipment includes Biotek Synergy 2 plate reader instruments, Grifols Triturus automated platform (x2) and Molecular Devices SpectraMax 380 and m5e plate readers, as well as MSD QuickPlex SQ120.
Our scientific team brings extensive, proven experience working with this popular platform to deliver high precision, high throughput assays to support testing of biologics, cell therapies, and gene therapies, and most often leverage ELISA to meet our clients’ most demanding ligand-binding assay challenges.
Learn how we can support your unique assay requirements with the ELISA method today.
See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.
Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
5927 S. Miami Blvd. Suite 100
Morrisville, NC 27560
919-381-6097
Fax 919-381-6099
1320 Soldiers Field Road
Boston, MA, 02135
Office 617-456-0700
Fax 617-456-0701
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
37 Kent St, Woolloongabba
Queensland, 4102, Australia
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.
Terms of Use | Privacy Notice
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
5927 S. Miami Blvd. Suite 100
Morrisville, NC 27703
919-381-6097
Fax 919-381-6099
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
37 Kent St,Woolloongabba
Queensland, 4102, Australia
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.
